Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on these data. This program extends Iovance's tumor infiltrating lymphocyte (TIL) cell therapy platform beyond its approved melanoma use. Iovance Biotherapeutics (NasdaqGM: IOVA) is putting fresh attention on its TIL platform, with lifileucel now moving from a pilot study in advanced sarcoma patients toward a potential registrational trial. The stock last closed at $5.13, with returns of 32.9% over the past week, 102.8% over the past month and 103.6% year to date. Over the past five years, the return stands at an 85.2% decline. That mix of sharp recent gains and longer term weakness helps explain why new clinical readouts are drawing close scrutiny from investors. The early sarcoma data and planned discussions with the FDA introduce a new potential use case that could matter for Io
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas [Yahoo! Finance]Yahoo! Finance
- Iovance (IOVA) Soars 33%, Hits All-Time High [Yahoo! Finance]Yahoo! Finance
- Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target [Yahoo! Finance]Yahoo! Finance
- UBS Raises PT on Iovance Biotherapeutics (IOVA) [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics: The High-Risk Cancer Stock I Think Could Change a Portfolio by 2036 [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- IOVA's page on the SEC website